GBGiulia Boscutti

Giulia Boscutti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giulia Boscutti has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PET imaging of antisense oligonucleotide distribution in rat and nonhuman primate brains using click chemistry

    by Brendon E. Cook, Thomas C. Pickel, Sangram Nag, Philippe N. Bolduc, Rouaa Beshr, Anton Forsberg Morén, Cathy Muste, Giulia Boscutti, Di Jiang, Long Yuan, et al.

    Determination of a drug’s biodistribution is critical to ensure that it reaches the target tissue of interest. This is particularly challenging in the brain, where invasive sampling methods may not be possible. Here, we present a pretargeted positron emission tomography (PET) imaging methodology that uses bioorthogonal click chemistry to determine the distribution of an antisense oligonucleotide (ASO) in the brains of rats and nonhuman primates after intrathecal dosing of ASO. A PET tracer, [ 18 F]BIO-687, bearing a click-reactive trans -cyclooctene was developed and tested in conjunction with a test Malat1 ASO conjugated with a methyltetrazine group. PET imaging in rats demonstrated that the tracer had good kinetic properties for PET imaging in the rodent central nervous system and could react to form a covalent linkage with high specificity to the methyltetrazine-conjugated ASO in vivo. Furthermore, the amount of PET tracer reacted by cycloaddition with the methyltetrazine was determined to be dependent on the concentration of ASO-methyltetrazine in rat brain tissue, as determined by comparing the PET imaging signal with the liquid chromatography–mass spectrometry signal in the tissue homogenates. The approach was evaluated in cynomolgus macaques using both the Malat1 test ASO and a candidate therapeutic ASO, BIIB080, targeting the microtubule-associated protein tau ( MAPT ) gene. PET imaging showed favorable tracer kinetics and specific binding to both ASOs in nonhuman primate (NHP) brain in vivo. These results suggest that the PET imaging tracer [ 18 F]BIO-687 could show the distribution of intrathecally delivered ASOs in the rat and NHP brains.


  • PET Radioligands for imaging of the PDE10A in human: current status

    by Giulia Boscutti, Eugenii A Rabiner, Christophe Plisson


  • Open Access

    Cell and Cell‐Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties

    by Chiara Nardon, Giulia Boscutti, Chiara Gabbiani, Lara Massai, Nicolò Pettenuzzo, Ambrogio Fassina, Luigi Messori, Dolores Fregona

    AuL10 ([AuIIICl2(dmdt)], dmdt = N,N‐dimethyldithiocarbamate) and AuL12 ([AuIIIBr2(esdt)], esdt = ethylsarcosine dithiocarbamate) are two extremely promising gold‐based anticancer compounds. Their mechanisms of action are still largely unknown although some specific hypotheses have been proposed. To shed light on their reactivity with probable biological targets, we report here on their interactions with serum albumin and calf‐thymus DNA, taken as model biomolecules. Quite unexpectedly, spectrophotometric investigations revealed substantially different patterns of interaction for these two gold complexes with the aforementioned biomolecules, probably arising from differences in redox chemistry. Afterwards, AuL12 was tested against A549 human non‐small‐cell lung carcinoma cells, evaluating its real‐time profile of cell‐growth inhibition by means of the xCELLigence Real‐Time Cell Analysis system. Measures of impedance by non‐invasive gold microelectrodes at the base of each well indicated that this gold complex inhibits cell proliferation after only 4 h of treatment, producing its cytotoxic effects probably at the membrane level.


  • CCK8 peptide-labeled Pluronic® F127 micelles as a targeted vehicle of gold-based anticancer chemotherapeutics

    by Chiara Nardon, Giulia Boscutti, Lisa Dalla Via, Paola Ringhieri, Vito Di Noto, Giancarlo Morelli, Antonella Accardo, Dolores Fregona

    The bioavailability and target selectivity of chemotherapeutics are significant issues in drug development. Here, we report the loading of the antiproliferative gold(III) complex, dibromo[ethyl-N-(dithiocarboxy-kS,kS′)-N-methylglycinato] gold(III) (AuL12), into the lipophilic core of micelles produced from the surfactant Pluronic® F127 (PF127). When AuL12 is encapsulated in PF127-based micelles it remains stable in saline solution up to 72 h with the gold center in the +3 oxidation state. PF127-based aggregates are efficient carriers as they enhance the water solubility of the gold complex. In vitro studies indicate that after micelle encapsulation, AuL12 gold complex preserves its antiproliferative efficacy. Moreover, by labeling the hydrophilic shell of micelles with the bioactive CCK8 peptide, the aggregates act as target-selective vehicles. In fact, cytotoxic activity towards the A431 cells overexpressing the CCK2 receptors is 10-fold higher than that towards the control cells.


    • 1 January 2014
      • Vol. 34  (1) , 487-92

    Beyond platinums: gold complexes as anticancer agents.

    by Chiara Nardon, Giulia Boscutti, Dolores Fregona

    The accidental discovery of the anticancer properties of cisplatin in the mid-1960s triggered the development of alternative platinum-based drugs. However, the platinum-based treatment of tumor diseases is massively hampered by severe side-effects and development of resistance. Sulfur-containing biomolecules play a significant role in platinum anticancer chemotherapy because of their high affinity to the platinum(II) ion. Sulfur is involved in the entire metabolic processing of platinum drugs. Strong and irreversible binding of cisplatin to intracellular thiolato ligands is considered a major step of inactivation, and reactions with sulfur donors in proteins are believed to affect enzymatic processes. Consequently, the development of novel metal-based compounds with a pharmacological profile different from that of clinically-established platinum drugs is a major goal of modern medicinal chemistry and drug design. Among the non-platinum antitumor agents, gold(III) complexes have recently gained increasing attention due to their strong tumor cell growth-inhibiting effects, generally achieved by exploiting non-cisplatin-like mechanisms of action. The real breakthrough is not simply the use of gold compounds to treat cancer, but the rational design of gold-based drugs which may be very effective, non-toxic and potentially selective towards cancer cells, their potential impact relying on the possible site-specific delivery in localized cancer, thus strongly improving cellular uptake and minimizing unwanted side-effects. Cancer cells are known to overexpress specific proteins and receptors needed for tumor growth. Among them, two integral plasma membrane proteins mediate the cellular uptake of di- and tripeptides and peptide-like drugs. They are present predominantly in epithelial cells of the small intestine, bile duct, mammary glands, lung, choroid plexus, and kidney but are also localized in other tissues and are up-regulated in some types of tumors. Accordingly, we have been designing gold(III)-peptide dithiocarbamato derivatives which combine both the antitumor properties and reduced side-effects of the previously reported gold(III) analogues with enhanced bioavailability and tumor selectivity achieved by exploiting peptide transporters. Our compounds showed interesting cytotoxic properties towards a number of cancer cell lines in vitro and in vivo on xenograft models, together with negligible organ and acute toxicity. With respect to their mechanisms of action, we identified mitochondria and proteasome as major in vitro and in vivo targets. These results allowed the filing of an international patent for the use of gold(III) peptidomimetics in cancer chemotherapy, as well as providing a solid starting point for them to enter phase I clinical trials in a few months.


  • Insights into the Reactivity of Gold–Dithiocarbamato Anticancer Agents toward Model Biomolecules by Using Multinuclear NMR Spectroscopy

    by Giulia Boscutti, Luciano Marchiò, Luca Ronconi, Dolores Fregona

    Some gold(III)–dithiocarbamato derivatives of either single amino acids or oligopeptides have shown promise as potential anticancer agents, but their capability to interact with biologically relevant macromolecules is still poorly understood. We investigated the affinity of the representative complex [AuIIIBr2(dtc‐Sar‐OCH3)] (dtc: dithiocarbamate; Sar: sarcosine (N‐methylglycine)) with selected model molecules for histidine‐, methionine‐, and cysteine‐rich proteins (that is, 1‐methylimidazole, dimethylsulfide, and N‐acetyl‐L‐cysteine, respectively). In particular, detailed mono‐ and multinuclear NMR studies, in combination with multiple 13C/15N enrichments, allowed interactions to be followed over time and indicated somewhat unexpected reaction pathways. Whereas dimethylsulfide proved to be unreactive, a sudden multistep redox reaction occurred in the presence of the other potential sulfur donor, N‐acetyl‐L‐cysteine (confirmed if glutathione was used instead). On the other hand, 1‐methylimidazole underwent an unprecedented acid–base reaction with the gold(III) complex, rather than the expected coordination to the metal center by replacing, for instance, a bromide. Our results are discussed herein and compared with the data available in the literature on related complexes; our findings confirm that the peculiar reactivity of gold(III)–dithiocarbamato complexes can lead to novel reaction pathways and, therefore, to new cytotoxic mechanisms in cancer cells.


  • Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy

    by Morelle Negom Kouodom, Giulia Boscutti, Marta Celegato, Marco Crisma, Sergio Sitran, Donatella Aldinucci, Fernando Formaggio, Luca Ronconi, Dolores Fregona


  • t-Butylsarcosinedithiocarbamato gold(III)-based anticancer agents: Design, in vitro biological evaluation and interaction with model biomolecules

    by Giulia Boscutti, Lisa Feltrin, Debora Lorenzon, Sergio Sitran, Donatella Aldinucci, Luca Ronconi, Dolores Fregona


  • Ruthenium(II/III)‐Based Compounds with Encouraging Antiproliferative Activity against Non‐small‐Cell Lung Cancer

    by Eszter M. Nagy, Andrea Pettenuzzo, Giulia Boscutti, Luciano Marchiò, Lisa Dalla Via, Dolores Fregona

    Hereby we present the synthesis of several ruthenium(II) and ruthenium(III) dithiocarbamato complexes. Proceeding from the Na[trans‐RuIII(dmso)2Cl4] (2) and cis‐[RuII(dmso)4Cl2] (3) precursors, the diamagnetic, mixed‐ligand [RuIIL2(dmso)2] complexes 4 and 5, the paramagnetic, neutral [RuIIIL3] monomers 6 and 7, the antiferromagnetically coupled ionic α‐[RuIII2L5]Cl complexes 8 and 9 as well as the β‐[RuIII2L5]Cl dinuclear species 10 and 11 (L=dimethyl‐ (DMDT) and pyrrolidinedithiocarbamate (PDT)) were obtained. All the compounds were fully characterised by elemental analysis as well as 1H NMR and FTIR spectroscopy. Moreover, for the first time the crystal structures of the dinuclear β‐[RuIII2(dmdt)5]BF4⋅CHCl3⋅ CH3CN and of the novel [RuIIL2(dmso)2] complexes were also determined and discussed. For both the mono‐ and dinuclear RuII and RuIII complexes the central metal atoms assume a distorted octahedral geometry. Furthermore, in vitro cytotoxicity of the complexes has been evaluated on non‐small‐cell lung cancer (NSCLC) NCI‐H1975 cells. All the mono‐ and dinuclear RuIII dithiocarbamato compounds (i.e., complexes 6–10) show interesting cytotoxic activity, up to one order of magnitude higher with respect to cisplatin. Otherwise, no significant antiproliferative effect for either the precursors 2 and 3 or the RuII complexes 4 and 5 has been observed.